Raise closed, search for fresh raises on Seedstage

Gaithersburg, MD

Supporting the development and expansion of cancer detection technologies through advanced diagnostics.

• Mission: Advancing early cancer detection through innovative blood tests that use biomarkers and AI-driven algorithms to identify cancers at earlier stages.  
• Innovation: Developed OneTest™, a multi-cancer early detection blood test that integrates results from six biomarkers, offering a cutting-edge approach to cancer screening.  
• Research and Expansion: Aiming to scale laboratory operations, enhance research capabilities, and increase accessibility and affordability of cancer detection tests.  
• Impact: Focused on detecting cancers that are not commonly screened for in the U.S., helping to catch diseases earlier and improve treatment outcomes.  
• Growth and Recognition: Gained recognition on the INC 5000 list as one of the fastest-growing companies, backed by venture capital and research grants, and serving both community and institutional needs with its Covid-19 testing services.  
• Technology Integration: Leverages artificial intelligence to assess cancer risks, demonstrating the company’s commitment to technological advancements in healthcare diagnostics.

20/20 GeneSystems is a healthcare and biotechnology company focused on advancing early cancer detection through its innovative OneTest, a multi-cancer early detection (MCED) blood test that uses biomarkers and AI-driven algorithms.

The company is raising funds to support the development and expansion of its cancer detection offerings, enhance its research capabilities, and continue scaling its laboratory operations.

The goal is to make these tests more widely accessible and affordable, helping to detect cancers earlier, particularly those that are not commonly screened in the U.S.

With a history of venture backing, research grants, and a growing base of users, 20/20 GeneSystems aims to drive innovation in cancer diagnostics and expand its market reach.

Company Info

20/20 GeneSystems, Inc. specializes in clinical laboratory testing, offering innovative cancer and Covid-19 testing solutions.

20/20 GeneSystems, Inc. operates in the life sciences sector, specializing in clinical laboratory testing. The company has developed OneTest™, a unique cancer screening test that integrates results from six biomarker tests into a single blood draw, utilizing artificial intelligence to assess the probability of various cancers. In addition to cancer testing, 20/20 GeneSystems provides Covid-19 testing services in the Mid-Atlantic Region, serving both community and institutional needs. The company has gained recognition for its rapid growth and has successfully raised significant capital through equity crowdfunding. As a privately-owned entity, it has been recognized on the INC 5000 list as one of the fastest-growing companies in the nation, showcasing its commitment to innovation and adaptation in the healthcare landscape.